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1. SUMMARY 
Lymphoid and non-lymphoid tissues accommodate defined numbers of dendritic cells (DCs). 
There, DC-life span is influenced by various components such as proliferation and cell 
division triggered by cytokines, maturation processes in response to extracellular 
inflammatory and microbial substances, as well as induction of migration and apoptosis. 
Previous work has demonstrated the importance of specific numbers of DCs in tissues, as 
changes of DC numbers or DC life span could alter immunity, tolerance or inflammation 
resulting in various immune diseases. However, currently it is still unknown how DC life span 
and homeostasis is regulated in vivo.  
RhoA is a member of Rho GTPase-family, which plays important roles in regulating 
cytoskeleton organization, proliferation, migration and survival. However, our current 
knowledge about RhoA-functions is based mostly on studies using dominant negative and 
constitutively active RhoA-mutants, which have possible unspecific effects on other members 
of the Rho GTPase family. Therefore, we used a LoxP/Cre recombinase approach to knock out 
RhoA selectively in DCs. Here we found that GTPase RhoA controlled the homeostasis of 
mature DCs, and deletion of RhoA caused significantly reduced numbers of CD8+CD11b- and 
CD11b+Esamhi DC subsets, while CD11b+Esamlo DCs remained largely unaltered. Loss of 
RhoA interfered with homeostatic proliferation, cytokinesis, survival and turnover of cDCs. 
By performing proteomic analysis, we found that a pro-survival PI3Kγ/Akt/BAD pathway was 
deregulated in RhoA-ko DCs. Taken together, our findings indicate that RhoA plays a critical 
role in regulating DC-homeostasis, deletion of which decreases DC numbers resulting in 
impaired immune protection.   
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2. ZUSAMMENFASSUNG 
Sowohl lymphoide, als auch nicht-lymphoide Organe beherbergen eine definierte Anzahl von 
dendritischen Zellen in speziellen Nischen. Dort wird die Lebensspanne der dendritischen 
Zellen von vielen Parametern, wie Proliferation und Zellteilung, die durch Zytokine gesteuert 
wird, Reifungsprozessen, die durch extrazelluläre entzündliche oder mikrobielle Substanzen 
reguliert werden, und durch Auswanderung oder Apoptose beeinflusst. 
Frühere Arbeiten konnten zeigen, dass eine genau definierte Anzahl dendritischer Zellen in 
Geweben eine große Rolle spielt, da eine experimentell veränderte Zellzahl starke 
Auswirkungen auf Immunität, Toleranz oder Entzündungen hatten, was in verschiedenen 
Immunkrankheiten resultierte. 
Allerdings sind die molekularen Mechanismen, welche die Homeostase und Lebensspanne 
von dendritischen Zellen regulieren, noch immer unklar. 
RhoA, ein Mitglied der Rho-GTPase-Familie, ist wichtig für die Organisation der Zytoskeletts, 
Proliferation, Wanderung und Überleben von Zellen. Allerdings beruht unser momentanes 
Wissen über RhoA auf Studien, die dominant-negative und konstitutiv-aktive RhoA-Mutanten 
verwendeten. Dabei ist nicht auszuschließen, dass die Mutanten unspezifische Effekte auf 
andere Mitglieder der Rho-GTPasen-Familie haben. Um dieses Problem zu umgehen, 
verwendeten wir einen LoxP/Cre-Rekombinase-Ansatz, um RhoA selektiv in dendritischen 
Zellen zu inaktivieren. 
Dabei haben wir beobachtet, dass RhoA die Homeostase von dendritischen Zellen reguliert, 
und dass die Deletion von RhoA eine starke Reduktion von CD11b-CD8+ und CD11b+Esamhi-
Subpopulationen von dendritischen Zellen bewirkt, während CD11b+Esamlo dendritische 
Zellen dadurch nicht beeinflusst werden. 
Der Verlust von RhoA beeinträchtigt die homeostatische Proliferation, Zytokinese, Überleben 
und Umsatz von klassischen dendritischen Zellen. Proteom-Analysen förderten einen defekten 
Signalweg, der das Überleben von Zellen reguliert zu Tage. Durch die Abwesenheit von RhoA, 
wurde der PI3Kγ/Akt/BAD Signalweg gestört. 
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Zusammenfassend lässt sich schlussfolgern, dass unsere Resultate RhoA als zentralen 
Regulator der dentrischen Zell-Homeostase identifizieren, dessen Deletion die Zahl der 
dendritischen Zellen unter die kritische Schwelle, die für einen effizienten Immunschutz 
notwendig ist, reduziert. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
3. INTRODUCTION 
3.1 Dendritic cells 
Since Ralph Steinman and Zanvil Cohn first discovered dendritic cells (DCs) in the late 1970s 
(Steinman and Cohn, 1973, 1974), DCs have been known as most powerful antigen presenting 
cells that bridge innate and adaptive immunity. DCs are widely distributed throughout the 
body and specialized for uptake, processing and presentation of antigens to T cells (Shortman 
and Liu, 2002). Immature DCs (iDCs) act as sentinels in peripheral tissues that continuously 
sample environmental antigens and pathogens. Upon encounter of pathogen, DCs will take up 
those foreign antigens and migrate into draining lymph nodes (dLNs). Meanwhile, DCs 
undergo a maturation process and up-regulate co-stimulatory molecules such as CD40, CD80 
and CD86. After maturation, mature DCs (mDCs) greatly lose their ability of taking up 
antigens but gain the powerful ability to process and present antigens to T cells. Therefore a 
protective immunity or tolerance is induced, depending on different DC subsets, maturation 
state and inflammatory signals (Reis e Sousa, 2006). 
3.1.1 DC subsets 
DCs are a heterogeneous group of cells that can be categorized into different subsets. The two 
main subsets are: plasmacytoid DCs (pDCs) and conventional or classic DCs (cDCs). pDCs 
are only a small population in the DC pool that share a similar origin with cDCs (Merad et al., 
2013). However, compared to cDCs, pDCs are long-lived cells and widely distributed in 
lymphoid and non-lymphoid tissues (O'Keeffe et al., 2002). They are characterized by 
producing large amounts of type I interferons (IFNs) in response of viral infections (Liu, 2005; 
O'Keeffe et al., 2002; Yoneyama et al., 2004). pDCs express endosomal Toll-like receptor 7 
and 9 (TLR7 and TLR9), which sense viral RNA and DNA respectively, therefore leading to 
type I IFN induction in order to clear viral infections (Guiducci et al., 2008). pDCs can be 
identified by their expression of Siglec-H and B220 on the cell surface (Zhang et al., 2006). 
The transcription factor E2-2 is specifically expressed in pDCs, which is critical for the 
development of pDCs, but not for cDCs (Cisse et al., 2008). It has been shown that E2-2 
deficiency completely blocked the development of pDC by using E2-2 knockout (ko) mouse 
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model (Cisse et al., 2008). pDCs express only low levels of CD11c, MHC-II and 
costimulatory molecules in the steady state, which makes them inefficient in presenting 
antigens to T cells (Merad et al., 2013). However, their precise contribution to immunity is 
still unclear (Reizis et al., 2011).  
cDCs are the typical DCs that Steinman originally discovered. They express high levels of 
CD11c, MHC-II and costimulatory molecules (CD40, CD80 and CD86), which are specialized 
for antigen processing and presentation. cDCs include several subsets that vary in phenotype 
and function (Diao et al., 2006). In lymphoid tissues, there are two major cDC subsets, CD8+ 
DCs and CD11b+ DCs. CD8+ DCs represent around 20-40% of spleen and dLNs cDCs, but 
around 70% of thymus DCs (Henri et al., 2001; Vremec et al., 2000). The biggest difference 
between those two DC subsets is that CD8+ DCs can effectively cross-present antigens via 
MHC-I molecules to CD8+ T cells (Shortman and Heath, 2010), while CD11b+ DCs are more 
efficient in activating CD4+ T cells although both DC subsets can present antigens via MHC-II 
molecules (Dudziak et al., 2007; Lin et al., 2008). On the other hand, CD8+ DCs produce high 
levels of IL-12 (Hochrein et al., 2001), which makes CD8+ DCs, rather than CD11b+ DCs, 
drive Th1 T cell responses (Maldonado-Lopez et al., 1999; Pulendran et al., 1999). The 
capacity of producing high amount of IL-12 and cross-presentation of exogenous antigens 
allows CD8+ DCs to induce cytotoxic T cell (CTL) responses. Thus CD8+ DCs are capable of 
engulfing dead cells, and cross-presenting cell-associated antigens on MHC-I molecules to 
CD8+ T cells in vivo (Iyoda et al., 2002; Schulz and Reis e Sousa, 2002). In spleen, CD11b+ 
DCs are comprised of two distinct Esamhi and Esamlo subsets, according to their expression of 
endothelial cell-specific adhesion molecule (ESAM) on cell surface (Lewis et al., 2011). 
CD11b+Esamhi DCs show typical DC morphology and surface maker expression profile, 
which are specialized for CD4+ T cell priming (Lewis et al., 2011). CD11b+Esamlo DCs 
preferentially express monocyte-specific genes such as Ly6c, colony-stimulating factor 1 
receptor (Csf1r), Csf3r and chemokine receptor CCR2, showing a pro-inflammatory cytokine 
response (Lewis et al., 2011). Notch2 is specifically required for the development of 
CD11b+Esamhi DCs, while Esamlo counterparts are Notch2 independent (Lewis et al., 2011). 
Besides Notch2, some other pathways are also required for the development of CD11b+Esamhi 
DCs, including lymphotoxin-β receptor (LTβR), retinoic acid (RA) and chemotactic receptor 
EBI2 signaling (Gatto et al., 2013; Kabashima et al., 2005; Klebanoff et al., 2013; Yi and 
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Cyster, 2013). Furthermore, Notch2-dependent CD11b+Esamhi DCs derive from DC 
precursors, while CD11b+Esamlo DCs are thought to derive from circulating monocytes or 
earlier monocytic progenitors (Lewis et al., 2011). However, the precise origin of 
CD11b+Esamlo DCs is still unknown. 
3.1.2 DC homeostasis 
cDCs play a critical role in both the priming of T cell immune responses and the induction of 
self-tolerance. On one hand, cDCs capture and present foreign antigens to T cells, therefore 
initiating adaptive immunity. On the other hand, cDCs could also process and present self-
antigen to induce tolerance. To maintain a balance between immunity and tolerance, it is 
crucial to keep normal numbers of cDCs with defined life spans in lymphoid organs. Previous 
studies have shown that constitutive ablation of cDCs or reduced cDC life spans led to 
defective priming of T cell response (Hou and Van Parijs, 2004; Jung et al., 2002; Ohnmacht 
et al., 2009; Park et al., 2006). Reduced CD4+ DC-subset results in impaired CD4+ T cell 
priming in EBI2 deficient mice (Yi and Cyster, 2013). Moreover, lack of cDCs also leads to 
inflammation and myeloproliferation (Birnberg et al., 2008), as well as T cell-mediated 
autoimmunity (Ohnmacht et al., 2009). Conversely, increased numbers of cDCs through 
inhibiting DC apoptosis, would lead to hyperactive B and T cell responses and autoimmunity 
due to defective tolerance induction (Chen et al., 2007; Chen et al., 2006; Nopora and Brocker, 
2002; Stranges et al., 2007). These studies above indicate the importance of maintaining cDC 
homeostasis in vivo. However, it is still unclear which molecular mechanism controls the cDC 
homeostasis in vivo. 
To maintain the homeostasis of a defined numbers of cDCs, the cDC pools in lymphoid organs 
need to get constant replenishment by DC precursors from the circulation (Liu et al., 2007). 
cDCs were initially thought to be non-dividing cells in lymphoid organs (Kamath et al., 2002; 
Kamath et al., 2000; Nopora and Brocker, 2002; Ruedl et al., 2000). However, recent studies 
have shown that about 5% of cDCs in spleen are proliferating at any time (Kabashima et al., 
2005; Liu et al., 2007). Therefore, cDCs in situ proliferation also plays an important role in 
maintaining cDCs homeostasis in spleen. Since cDCs have a rapid turnover rate (half-life, 3 
days) in spleen (Kamath et al., 2000), cell cycle control might also play a role in regulating 
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cDC generation from their circulating progenitor cells. Therefore, in order to fully understand 
mechanisms of DC homeostasis maintenance, it is important to find out how in situ 
proliferation and cell cycle is regulated in cDC.  
3.1.2 DC ontogeny 
Most DCs originate from hematopoietic stem cells in the bone marrow (BM). Hematopoietic 
stem cells can give rise to a progenitor called the macrophage and dendritic cell progenitor 
(MDP), which is the common precursor for monocytes, macrophages and DCs (Fogg et al., 
2006) (Fig. 1). MDPs were initially identified as Lin-cKitloCX3CR1+Flt3+ (Fogg et al., 2006). 
MDPs differentiate into monocytes and another progenitor called common DC progenitor 
(CDP) (Fig. 1), which is identified as Lin-cKitloCD115+Flt3+ cell (Naik et al., 2007; Onai et al., 
2007). CDPs exclusively give rise to cDCs and pDCs, but not monocytes or macrophages 
(Onai et al., 2007) (Fig. 1). In in vitro Flt3L-supplemented BM cultures, CDPs can be 
generated from BM cells, which were also called proDC (Naik et al., 2007). Then CDPs 
further give rise to a cDC-restricted precursor called pre-cDC, which can be recognized as Lin-
CD11c+MHC-II-CD43+Sirpαint in BM and spleen (Naik et al., 2006; Naik et al., 2007). These 
cells are able to differentiate into CD8+ and CD11b+ cDCs in vivo and in vitro (Naik et al., 
2006; Naik et al., 2007). In steady state, pre-cDCs have been identified in BM (0.2%), blood 
(0.03%), lymph nodes (0.03%) and spleen (0.05%) with different frequencies (Liu and 
Nussenzweig, 2010; Liu et al., 2009). pDCs and pre-cDCs continually migrate through the 
blood into lymphoid tissues where these pre-cDCs further differentiate into CD8+ and CD11b+ 
cDCs (Liu et al., 2009) (Fig. 1). Pre-cDCs can also give rise to CD103+ and CD11b+ cDCs in 
skin, lung, kidney and intestine (Bogunovic et al., 2009; Ginhoux et al., 2009) (Fig. 1).  
The granulocyte-macrophage colony-stimulating factor (GM-CSF) and fms-like tyrosine 
kinase 3 ligand (Flt3L) are two best-characterized cytokines regulating DC homeostasis. GM-
CSF plays an important role in differentiation of hematopoietic progenitor cells (HPCs) into 
DCs in vitro (Caux et al., 1996; Inaba et al., 1992; Sallusto and Lanzavecchia, 1994). Injection 
of GM-CSF caused significantly increased numbers of DCs in vivo, suggesting its role in 
promoting DC expansion (Daro et al., 2000). Therefore, GM-CSF has widely been used for 
generating large numbers of DCs in vitro. However, lack of GM-CSF or GM-CSF receptor 
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(GM-CSFR) caused only a small decrease of DC numbers (Vremec et al., 1997). Interestingly, 
in GM-CSF or GM-CSFR deficient mice, CD103+ and CD11b+ DC subsets significantly 
decreased in non-lymphoid organs by apoptosis, indicating that GM-CSF can promote survival 
of those DC subsets (Greter et al., 2012; King et al., 2010; Kingston et al., 2009). Similar to 
GM-CSF, Flt3L is another critical cytokine required for the development of both pDCs and 
cDCs (Shortman and Naik, 2007). Injection of Flt3L dramatically increased DC numbers in 
vivo (Maraskovsky et al., 1996). Flt3 (also called CD135) is the receptor of Flt3L which is 
expressed on various DC-committed progenitor cells, such as MDPs, CDPs and pre-cDCs 
(Merad et al., 2013). In Flt3L- or Flt3-deficient mice, the numbers of DC progenitor cells, 
pDCs and cDCs were significantly decreased, while B and T cells remained unaltered 
(Kingston et al., 2009; McKenna et al., 2000; Waskow et al., 2008), suggesting its essential 
role in maintaining DC homeostasis. In addition, Flt3 also contributes to maintain normal 
numbers of DCs in vivo by regulating DC proliferation (Waskow et al., 2008). 
 
Figure 1. Development of DCs in steady state. 
The cDCs, pDCs, and monocytes derive from MDPs in the BM. MDPs give rise to monocytes and CDPs, with 
the latter further develop into pDCs and pre-cDCs. Then monocytes, pDCs and pre-cDCs will migrate through 
blood and seed in lymphoid or non-lymphoid tissues, where pre-cDCs eventually differentiate into CD8+ (or 
CD103+) and CD11b+ cDCs (Satpathy et al., 2012). 
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3.2 RhoA 
Small Rho GTPases are a family of GTP-binding proteins that are found in all eukaryotic cells 
(Jaffe and Hall, 2005). The Rho GTPase family consists of 22 different members, in which 
RhoA, Cdc42 and Rac1 are the best characterized (Jaffe and Hall, 2005; Tybulewicz and 
Henderson, 2009). In this study, we mainly focus on RhoA functions in DCs. RhoA regulates 
multiple cellular functions in response to various external stimuli through cycling between 
inactive GDP-bound state and active GTP-bound state (Heasman and Ridley, 2008) (Fig. 2). 
Activation of RhoA is regulated by its specific guanine-nucleotide-exchange factors (GEFs), 
guanine nucleotide dissociation inhibitors (GDIs) and GTPase-activating proteins (GAPs) (Fig. 
2). GEFs promote GTP binding to RhoA, which leads to RhoA activation. In contrast, both 
GAPs and GDIs cause RhoA inactivation through promoting hydrolysis of GTP and inhibiting 
GDP dissociation from RhoA respectively (Fig. 2). Activated RhoA recruits a variety of 
downstream effectors (e.g. ROCK, Citron kinase and mDia1) to regulate cytoskeleton 
organization, proliferation, migration and cell survival (Miller et al., 2012; Reuveny et al., 
2004; Worthylake and Burridge, 2003) (Fig. 2).  
 
Figure 2. Activation and function of RhoA.  
RhoA is cycling between the inactive GDP-bound state and active GTP-bound state in response of environmental 
stimuli. This cycling is tightly regulated by Rho guanine nucleotide exchange factors (GEFs), Rho GTPase-
activating proteins (GAPs) and Rho GDP dissociation inhibitors (GDIs). Upon activation, the GTP-bound RhoA 
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can activate a large panel of downstream effectors to transduce signals that affect cell cytoskeleton organization, 
adhesion, cell cycle, survival and gene transcription (Zhou and Zheng, 2013). 
Currently, most of our knowledge on RhoA functions is based on studies applying C3 
transferase, overexpression of dominant-negative or constitutively active mutants to inhibit or 
excessively activate RhoA (Heasman and Ridley, 2008). However, these methods have 
nonspecific effects on other Rho GTPases. For example, C3 transferase inhibits activation of 
RhoA, as well as RhoB and RhoC, although it shows only a minor effect on other Rho 
GTPases (Cdc42 and Rac1) (Chardin et al., 1989; Mohr et al., 1992). And some studies have 
also revealed that overexpression of dominant negative mutants of RhoA may have 
nonspecific effects on Rac1 and/or Cdc42 (Heasman and Ridley, 2008; Wang and Zheng, 
2007). Considering these limitations, it is necessary to apply RhoA specific ko models for 
RhoA functional studies. Recently, there have been several studies generating cell type 
specific RhoA-ko mice. In keratinocytes, RhoA deficiency did not affect skin development, 
but the contraction and directed migration of keratinocytes was markedly impaired (Jackson et 
al., 2011). In primary mouse embryonic fibroblasts (MEFs), deletion of RhoA led to 
significantly reduced proliferation due to defective cytokinesis (Melendez et al., 2011). RhoA 
deletion also caused strongly reduced B cells in lymphoid organs, suggesting its essential role 
in B cell development, however the proliferation of B cells was not affected (Zhang et al., 
2012). Furthermore, RhoA deficiency resulted in a cytokinesis failure in HPCs, associated 
with accumulated multinucleated cells (Zhou et al., 2013). Obviously, these studies indicate 
that RhoA function is cell type dependent, and some of the previously proved cellular roles of 
RhoA might not be applied to other types of cells in vivo. 
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3.3 Aim of the project 
In this study, we wanted to investigate functions of RhoA in DCs. Previous studies have 
shown that RhoA played an important role in the regulation of morphology and function of 
DCs by applying C3 toxin and a dominant-negative mutant (Kobayashi et al., 2001; Shurin et 
al., 2005). However, the specific role of RhoA in DCs is still largely unknown. So in our lab, 
we generated DC-specific RhoA-ko mice by crossing CD11c-Cre mice with RhoA floxed 
mice. With this mouse model, we were able to analyze if there were any defects in the 
development, migration, proliferation and survival of DCs in absence of RhoA and the 
underlying mechanisms behind those defects. 
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4. MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Antibodies 
4.1.1.1 Antibodies for flow cytometry 
Specificity (anti-mouse) Conjugate Clone Supplier 
CD3e PE 145-2C11 eBioscience 
CD4 PE 
PE-cy7 
GK1.5 
GK1.5 
BD Pharmingen 
eBioscience 
CD8a PE 
Pacific-Blue 
APC-eFluor 780 
53-6.7 
 
53-6.7 
eBioscience 
Invitrogen 
eBioscience 
CD11b APC-eFluor 780 M1/70 eBioscience 
CD11c FITC 
PE 
APC 
PE-cy7 
N148 
N148 
N148 
N148 
eBioscience 
eBioscience 
eBioscience 
eBioscience 
CD16/32 (Fc block)  2.4G2 BD Pharmingen 
CD19 PE 1D3 BD Pharmingen 
CD40 APC 1C10 eBioscience 
CD43 FITC 
Biotin 
S7 
S7 
BD Pharmingen 
BD Pharmingen 
B220 PE RA3-682 BD Pharmingen 
CD45RA PE 14.8 BD Pharmingen 
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CD45.1 FITC 
PE 
Pacific Blue 
A20 
A20 
A20 
BD Pharmingen 
eBioscience 
Biolegend 
CD45.2 APC 104 Biolegend 
CD80 PE 16-10A1 BD Pharmingen 
CD86 PE GL-1 eBioscience 
CD103 PE M290 BD Pharmingen 
CD135 (Flt3) PE 
Biotin 
A2F10 
A2F10 
eBioscience 
eBioscience 
CD172α (Sirpα) APC P84 BD Pharmingen 
NK1.1 PE PK136 BD Pharmingen 
Gr-1 PE R86-8C5 BD Pharmingen 
MHC-II (IA/IE) FITC 
PE 
APC 
Per-CP 
M5/114.15.2 
M5/114.15.2 
M5/114.15.2 
M5/114.15.2 
Biolegend 
eBioscience 
Biolegend 
eBioscience 
PDCA1 APC 129c1 Biolegend 
Esam PE 1G8 eBioscience 
Ki67 PE B56 BD Pharmingen 
F4/80 PE BM8 eBioscience 
BrdU FITC  BD Pharmingen 
Ly6C FITC AL-21 BD Pharmingen 
Streptavidin Cy5 CALTAG Life Technologies 
 APC-cy7  BD Pharmingen 
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4.1.1.2 Antibodies for Western blot 
Specificity Host Dilution Supplier 
β-actin Rabbit 1/1000 Cell Signaling  
RhoA Rabbit 1/1000 Cell Signaling 
PI3Kγ Rabbit 1/1000 Cell Signaling 
Akt Rabbit 1/1000 Cell Signaling 
Phospho-Akt Rabbit 1/1000 Cell Signaling 
Bad Rabbit 1/1000 Cell Signaling 
Phospho-Bad Rabbit 1/1000 Cell Signaling 
Rabbit Donkey 1/2000 Jackson Lab 
4.1.2 Chemicals 
Chemicals were purchased from Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany) or 
Sigma-Aldrich (St. Louis, MO, USA) unless stated differently. All buffers were prepared with 
double distilled water (dH2O). 
4.1.3 Consumables 
Cell strainer (100m) BD, San Jose, CA, USA 
Mesh filter (41m) Reichelt Chemietechnik, Heidelberg, Germany 
Disposable syringes (1ml) Braun, Melsungen, Germany 
Injection needles 26G Terumo Medical Corporation, Tokyo, Japan 
Tubes of 1.5 ml and 2.0 ml Eppendorf, Hamburg, Germany 
FACS 5 ml tubes SARSTEDT, Nümbrecht, Germany 
15 ml and 50 ml falcon tubes Greiner, Frickenhausen, Germany 
PCR tubes (0.2 ml) Nunc, Wiesbaden, Germany 
Other materials and plastic wares were purchased from BD, Nunc (Wiesbaden, Germany) and 
Greiner (Frickenhausen, Germany). 
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4.1.4 Devices 
Analytic scale (Adventurer, Ohaus Corp., Pine Brooks, NJ, USA), automatic pipettors (Integra 
Biosciences, Baar, Switzerland), bench centrifuge (Centrifuge 5415 D, Eppendorf, Hamburg, 
Germany), CASY cell counter (Roche, Basel, Switzerland), centrifuge (Rotixa RP, Hettich, 
Tuttlingen, Germany), chemical scale (Kern, Albstadt, Germany), flow cytometer 
(FACSCantoII, FACSAria, BD), incubator (Hera cell, Heraeus Kendro Laboratory Products, 
Hanau, Germany), laminar airflow cabinet (Heraeus), magnetic stirrer (Ika Labortechnik, 
Staufen, Germany), PCR-machine (Biometra, Goettingen, Germany), pH-meter (Inolab, 
Weilheim, Germany), pipettes (Greine, Frickenhausen, Germany), power supply (Amersham 
Pharmacia, Piscataway, NJ, USA), vacuum pump (KNF Neuberger, Munzingen, Germany), 
water bath (Grant Instruments Ltd., Barrington Cambridge, UK). All other devices are 
mentioned in the methods section. 
4.1.5 Medium and solutions 
ACK buffer 8.29 g NH4Cl   
1 g KHCO3   
37.2 mg Na2EDTA   
H2O ad 1 L 
pH 7.2-7.4 adjusted with 1 N HCl  
Sterilized by 0.2 m filtration 
BMDC medium RPMI 1640 (PAA, Pasching, Austria) 
2 mM glutamine 
100 U/ml penicillin 
100 μg/ml streptomycin 
10% FCS 
20 ng/ml GM-CSF 
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PBS (Phosphate buffered saline) 150 mM NaCl 
10 mM Na2HPO4   
2 mM KH2PO4   
pH 7.4  
Adjusted with 5 N NaOH 
FACS buffer PBS 
2% FCS (v/v)  
0.01% NaN3 (v/v) 
MACS buffer Dulbecco’s PBS without Ca2+/Mg2+ (Gibco) 
0.5% FCS (v/v)   
2 mM EDTA 
50x TAE buffer 
 
242 g Tris   
57.1 ml 100% acetic acid (v/v)  
100 ml 0.5 M EDTA  
pH 8.0 
H2O ad 1 L 
10x Gitocher buffer 
 
670 mM Tris pH 8.8  
166 mM (NH4)2SO3  
65 mM MgCl2   
0.1 % Gelatin 
Digestion mix for genotyping 
 
1x Gitocher buffer   
0.5 % Triton-X   
1 % β-mercaptoethanol  
0.4 mg/ml Proteinase K 
H2O 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5x Cresol red buffer 250 mM KCl 
50 mM Tris/HCl pH 8.3 
43% glycerol 
2 mM Cresol-red 
7.5 mM MgCl2 
Western blot solutions:  
Lysis buffer 
 
50 mM Tris/HCl pH 8.8   
150 mM NaCl   
1 % NP40   
1/100 protease inhibitor cocktail  
1 mM PMSF 
Running buffer 
 
25 mM Tris Base  
192 mM Glycine  
0.1 % SDS 
H2O   
Separating gel 12% 
 
30 % Acrylamid 
1.5 mM Tris/HCl pH 8.8   
1 % SDS   
1 % APS   
0.04 % TEMED 
H2O   
Stacking gel 5% 
 
30 % Acrylamid 
1 M Tris/HCl pH 6.8   
1 % SDS 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1 % APS   
0.1 % TEMED 
H2O   
Transferring buffer 
 
25 mM Tris-Base  
192 mM Glycine  
20 % Methanol  
0.002 % SDS 
PBST 
 
PBS   
0.05 % Tween-20 
Blocking buffer PBST 
5 % non-fat milk 
4.1.6 Mice 
All mice were bred and maintained at the animal facility of the Institute for Immunology 
(LMU, Munich) in accordance with established guidelines of the Regional Ethics Committee 
of Bavaria. 
4.1.6.1 C57BL/6  
C57BL/6 mice were originally obtained from the Jackson Laboratory (Bar Harbor, USA). 
C57BL/6 mice expressing congenic markers CD45.1 or CD45.2 were both used in this study.  
4.1.6.2 RhoA-ko and CD11c-Cre mice 
To generate mice with DC-specific RhoA deficiency, RhoAfl/fl mice (Jackson et al., 2011) 
provided by Cord Brakebusch (University of Copenhagen, Copenhagen, Denmark) were 
crossed with CD11c-Cre mice (Caton et al., 2007) provided by Boris Reizis (Columbia 
University, New York, USA). These mice were abbreviated as RhoA-ko mice. CD11c-Cre 
mice were used as control mice in this study. 
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4.2 Methods 
4.2.1 Cellular and immunological methods 
4.2.1.1 Annexin V apoptosis detection 
Apoptosis is a programmed cell death characterized by losing integrity of cell membrane. 
Annexin-V combined with 7-AAD is widely used to detect apoptotic cells due to its ability of 
binding to phosphatidylserine (PS). In viable cells, PS is located on the cytosolic side of cell 
membrane. When apoptosis occurs, PS flips to the extracellular of cell membrane, which can 
be detected by fluorescently labeled Annexin-V. In early stages of apoptosis, the cell 
membrane excludes viability dye 7-AAD, therefore Annexin-V single positive cells (7-AAD 
negative) are in early stages of apoptosis. During late-stage of apoptosis, 7-AAD can pass 
through cell membrane and bind the nuclei due to damaged cell membrane integrity. Therefore 
Annexin-V and 7-AAD double positive cells are in late stages of apoptosis. 
4.2.1.2 BrdU pulse-chase  
BrdU is an analog of thymidine that can be incorporated into newly synthesized DNA by 
proliferating cells. A specific anti-BrdU fluorescent antibody is used to detect cells 
incorporated BrdU. The percentages of BrdU-labeled cells are then measured by flow 
cytometry. To measure the DC turnover rate, a BrdU pulse-chase experiment is performed. 
During the pulse phase, BrdU is administrated, and the percentage of BrdU+ DCs increases 
over time. During the BrdU-free chase phase, the percentage of BrdU+ DCs declines over time. 
This provides information of DC turnover rate and DC longevity. Briefly, mice were injected 
intraperitoneally (i.p.) with 1 mg BrdU in 100 l PBS, and then continuously received 
drinking water containing 0.8 mg/ml BrdU for 3 days. Then giving mice normal drinking 
water, at various time points, spleen cells were harvested and stained with antibodies against 
cell surface molecules. After washing, cells were fixed and permeabilized with 
cytofix/cytoperm buffer (BD Bioscience). Following washing, cells were incubated with 
DNase I for 1h at 37°C. The cells were then incubated at RT with FITC conjugated BrdU 
antibody (BD Biosciences, San Diego, CA) for 30 minutes. After washing, cells were re-
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suspended and analyzed by flow cytometry.  
4.2.1.3 Flow cytometry and cell sorting 
Flow cytometry (Fluorescence-Activated Cell Sorting, FACS) is a method that can evaluate 
various cell characteristics such as cell size (forward scatter, FSC), granularity (side scatter, 
SSC) and marker expression. Single cell suspensions are stained with fluorescent antibodies 
against cell surface or intracellular antigens. Antibodies labeled cells pass by a laser beam and 
then several detectors. A variety of cell information such as FCS, SSC and fluorescence 
intensity are acquired and used to analyze immune cell phenotype and functions.  
In brief, 2x106 cells were placed into a V-bottom 96 well plate and washed with PBS. Cells 
were incubated with 50 μl of FACS buffer containing certain fluorescent antibodies for 20 min 
at 4°C in the dark. To remove unbound antibodies, cells were washed with FACS buffer, and 
then re-suspended in 150 μl FACS buffer. Cells stained with biotinylated antibodies can be 
further detected with a fluorescent streptavidin in a second staining step. For intracellular 
staining, cells are fixed and permeabilized first with BD Cytofix/Cytoperm buffer according to 
the manufacturer’s protocol. Data were acquired through running samples in FACSCanto II 
(BD Bioscience) with three lasers (488, 633 and 405 nm). 
Cell sorting is an advanced flow cytometry used to identify and collect certain interest cell 
populations. By using FACSAria instrument (BD), the population of interest can be identified 
and electrical charged, and then collected by electrostatic droplet deflection. FACS data were 
analyzed with FlowJo software (TreeStar, Ashland, OR, USA). 
4.2.1.4 Histology 
Spleens were embedded in O.C.T. compound (Sakura Finetek) and frozen immediately in 
liquid nitrogen. Spleens were cut into 5 μm sections using a cryostat at -15°C (Jung Frigocut 
2800 E, Leica) and air-dried overnight at RT. Spleen sections were fixed with ice-cold acetone 
at -20°C for 10 min, then air-dried for at least 1 hour. After 15 min rehydrate in PBS 
containing 0.25% BSA, sections were blocked in PBS containing 0.25% BSA and 10% mouse 
serum for 15 min at RT. After blocking, spleen sections were incubated with rat anti-mouse 
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CD8-FITC, CD11c-PE, B220-APC and Moma-Biotin antibodies for 30 min at RT. After 
washing, sections were further stained with streptavidin-cy5 for 30 min at RT. Then spleen 
sections were directly mounted in Fluoromount-G (SouthernBiotech) after washing. At last, 
spleen sections were visualized using an Olympus BX41TF-5 microscope equipped with F-
View II Digital Micro camera (Olympus). 
4.2.1.5 ImageStream 
The ImageStream is a novel technology that combines advantages of flow cytometry and 
microscopy. It can provide both accurate statistical analysis and images of cells at the same 
time. ImageStreamX Mark-II (Amnis Corporation, Seattle, WA, USA) equipped with 5 lasers 
(405, 488, 561, 642 and 785 nm) is capable of detecting side scatter, bright field, and 4 
fluorescent channels.  
For cell cycle analysis, 3x106 BMDCs or ex vivo isolated spleen DCs were stained with 
antibodies against surface markers at 4°C for 20 min. After washing, cells were fixed in 
Cytofix/Cytoperm buffer at 4°C for 30 min. Then, the nuclei were stained with DAPI in 
Perm/Wash buffer at 4°C for 10 min. After washing, cells were re-suspended with 50 l PBS 
and analyzed by ImageStreamX Mark-II. 100,000 cells of each sample were recorded. Flow 
cytometry and image data were acquired and analyzed by Amnis INSPIRE and IDEAS 
software respectively. Different populations can be discriminated based on combined features 
of size, shape, fluorescent intensity, etc.  
4.2.1.6 Generation of BMDC and Flt3L-DC 
Bone marrow derived DCs (BMDCs) are generated from BM cells in the presence of GM-CSF. 
Femur and tibiae were taken from mice, and BM cells were flushed out using a 0.45x12 mm 
needle with BMDC-medium (see 4.1.5). Red blood cells were lysed in ACK buffer (see 4.1.5) 
for 2 min at RT. Then 10-15x106 cells were cultured in 20 ml BMDC-medium per 100mm 
plate for 10-13 days. The medium was refreshed at day3 and 7. The purity and maturation 
level of BMDCs were analyzed by flow cytometry based on the expression of CD11c, MHC-II, 
CD40 and CD86. 
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Flt3L-derived DCs were generated from BM cells as well in the presence of Flt3L. BM was 
extracted from femur and tibiae, and red blood cells were lysed in ACK buffer. BM cells were 
cultured at 1x106 cells/ml in RPMI 1640 medium (with 10% FCS, Pen-Streptomycin and 
50μM 2-mercaptoethanol) in the presence of 20 ng/ml homemade recombinant murine Flt3L. 
At day 3, cells were collected and used for pro-DC and pre-cDC sorting as described (Naik et 
al., 2007).  
4.2.1.7 Magnetic cell sorting (MACS) 
MACS is a technique used for isolating different cell subpopulations according to their 
specific surface markers. First, the target cells are labeled with specific monoclonal antibodies 
that are conjugated to magnetic microbeads. Then, the cell suspension is loaded onto a MACS 
column, which is placed in the magnetic field of a MACS separator. The magnetically labeled 
positive cells are retained within the column. The unlabeled negative cells will run through the 
column. After removing from the magnetic field, the magnetically labeled positive cells can be 
eluted from column. Therefore, the positive and negative cells are collected separately.  
In this study, MACS was utilized to isolate CD11c-positive DCs (CD11c microbeads, 
Miltenyi Biotec, Germany) from spleen. For DC precursor sorting, spleen cells were labeled 
with biotin-conjugated antibodies against lineage markers (CD3, CD19, B220 and NK1.1). 
Then streptavidin microbeads (Miltenyi Biotec, Germany) were used to isolate lineage 
negative cells by negative selection. The enriched lineage negative cells can be further used 
for pre-cDC sorting. All procedures were performed according to the manufacturer’s 
instructions. 
4.2.1.8 Mixed bone marrow chimera 
BM cells were harvested from femurs and tibiae of CD11c-Cre (CD45.1) and RhoA-ko 
(CD45.2) donor mice 6-8 weeks of age. The red blood cells were lysed with ACK buffer, then 
5x106 total 50:50 mixed BM cells were injected intravenously (i.v.) into lethally irradiated 
(split dose: 600 rad at day -1 and 0) recipient B6 mice (CD45.2, 10-12 weeks of age). After 
BM transfer, recipient mice received drinking water containing 1.2 g/l of Neomycin for 4 
weeks. Mixed BM chimeras were analyzed or used for BrdU pulse-chase experiment 8 weeks 
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after fully BM reconstitution. 
4.2.1.9 Single cell suspension preparation 
Lymph nodes (pooled axillary, brachial and inguinal, LNs), spleen and thymus were collected 
respectively, and enzymatically digested using a solution containing Liberase DL (0.125 
mg/ml) and DNase I (0.2 mg/ml, both from Roche, Basel, Switzerland). After a 30 min 
digestion at 37C, these organs were smashed and filtered through a cell strainer (100m) to 
obtain a single cell suspension. The red blood cells were lysed using ACK buffer. Cell 
numbers were determined using CASY cell counter (Roche, Basel, Switzerland). 
4.2.1.10 TUNEL assay 
TUNEL (TdT-mediated dUTP-biotin nick end labeling) assay is usually used to detect DNA 
fragmentation in apoptotic cells.  Fragmented DNA can be labeled with digoxigenin-
nucleotide by using terminal deoxynucleotidyl transferase (TdT), and then detected with an 
anti-digoxigenin fluorescent antibody. TUNEL-positive DCs in spleen were detected using 
ApopTag Fluorescein In Situ Apoptosis Detection Kit (Millipore; Billerica, Massachusetts, 
USA) according to the manufacturer’s instructions. Briefly, spleen cell suspension was first 
labeled with fluorescent antibodies against surface markers, and then cells were fixed in 1% 
paraformaldehyde in PBS for 30 minutes at RT. Cells were permeabilized with 0.1% Triton X-
100 on ice for 2 minutes. After washing, cells were incubated with working strength TdT 
enzyme for 30 minutes at 37°C. The reaction was stopped using stop/wash buffer. After three 
washes in PBS, cells were incubated with anti-digoxigenin Fluorescein conjugate for 30 min at 
RT. And then the DNA of cells was stained with DAPI. TUNEL-positive DCs were detected 
by flow cytometry. 
4.2.1.11 ELISA test of Flt3L 
Serum levels of Flt3L in Cre control and RhoA-ko mice was measured using mouse Flt-3 
Ligand ELISA kit (catalog #DY427, R&D system) according to the manufacturer’s 
instructions. Serum was first diluted at 1:20, and then used for ELISA measurement. The 
optical density was determined at 450 nm with Kinetic ELISA Microplate Reader (Molecular 
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Devices, CA, USA).  
4.2.2 Molecular biology methods 
4.2.2.1 Agarose gel electrophoresis 
Agarose gel electrophoresis is used to separate a mixed DNA fragments according to their size. 
A 100 bp DNA ladder (New England Biolabs, Ipswich, MA, USA) was applied to determine 
the size of different DNA fragments. DNA mixture was loaded onto a 1% of agarose gel and 
separated by applying a constant voltage to an electrophoresis chamber filled with TAE buffer 
(see 4.1.5). DNA was visualized under UV light by addition of ethidium bromide (0.5 μg/ml). 
4.2.2.2 Polymerase chain reaction (PCR) and genotyping 
PCR is a common molecular biology technology used to rapidly amplify a specific DNA 
sequence. In this study, PCR was used to check phenotypes of different mouse strains. 
Genomic DNA of mice was extracted by incubating a small piece of mouse tail in digestion 
buffer (see 4.1.5) at 55°C for 6 hour, followed by deactivation of proteinase K at 95°C for 5 
min. The following primers were used to test Cre and RhoA flox gene: 
Table 1: primers for genotyping 
Cre 
Forward GGACATGTTCAGGGATCGCCAGGCG 
Reverse GCATAACCAGTGAAACAGCATTGCTG 
RhoA flox 
Forward AGCCAGCCTCTTGACCGATTTA 
Reverse TGTGGGATACCGTTTGAGCAT 
PCR mix: 
0.2 l forward primer (100 pmol/l)  
0.2 l reverse primer (100 pmol/l)  
6 l Cresol red buffer with MgCl2 (see 4.1.5)   
1.0 l DNA   
5 U/ml PANScript DNA polymerase 
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dH2O ad 29 l 
PCR reactions were performed using the following program: 
Step 1: 95°C 5 min 
Step 2: 95°C 30 sec 
Step 3: 55°C 30 sec 
Step 4:  72°C 30 sec         (back to step 2 for 35 cycles) 
Step 5:  72°C 10 min 
Step 6: 4°C Pause 
4.2.2.3 Isolation of mRNA and cDNA synthesis 
Total RNA was extracted from 1x106 cells using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to manufacturer’s instructions. The remaining DNA was removed by on-
column DNase I digestion. The concentration and quality of RNA were measured by a 
NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The mRNA 
was reverse transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen) 
according to the instructions of manufacturer. 
4.2.2.4 Quantitative PCR (qPCR) 
 qPCR is used to determine relative transcription of certain genes. In this study, the TaqMan 
probes were used for qPCR examination. The fluorescent-labeled TaqMan probes give a 
signal only after their binding to a specific cDNA sequence. The strength of signal is 
correlated with initial amount of cDNA. The cycle threshold (Ct) value represents minimal 
numbers of PCR cycle required for detectable signal strength.  
The TaqMan assay was performed with the LightCycler TaqMan Master Kit and the Universal 
ProbeLibrary Set mouse (Roche) according to the manufacturer’s instructions on a CFX96 
Real Time System (Bio-Rad, Hercules, CA, USA). The primers and probes are listed in table 2. 
The housekeeping gene HPRT was used as endo-gene for normalizing. The relative expression 
of target genes was calculated by using the 2-ΔΔCt method.  
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Table 2. Primers and probes for qPCR 
Genes Primers Sequence Probe 
HPRT 
Forward TCCTCCTCAGACCGCTTTT 
95 
Reverse CCTGGTTCATCATCGCTAATC 
RhoA 
Forward CCTGTGTGTTTTCAGCACCTT 
46 
Reverse ACCTCTGGGAACTGGTCCTT 
PI3Kγ 
Forward GGAGACTGAATCTCTGGACCTG 
29 
Reverse GTGGCATCCTTTACAATCTCG 
Ripk1 
Forward TACCTCCGAGCAGGTCAAAT 
50 
Reverse AAACCAGGACTCCTCCACAG 
Ripk3 
Forward CCGACGATGTCTTCTGTCAA 
6 
Reverse GACTCCGAACCCTCCTTTG 
Glud1 
Forward GGTCATCGAAGGCTACCG 
76 
Reverse TCAGTGCTGTAACGGATACCTC 
TNF-α 
Forward CCCCAAAGGGATGAGGTAGT 
104 
Reverse CTAACCCGTCTTGCTTGTGAG 
Fth1 
Forward GCCAGAACTACCACCAGGAC 
75 
Reverse CCACATCATCTCGGTCAAAAT 
TNFR1 
Forward TGTCAATTGCTGCCCTGTC 
40 
Reverse GATGTATCCCCATCAGCAGAG 
4.2.2.5 Western blot 
Total proteins were extracted from 1x106 BMDCs or ex vivo isolated spleen DCs using protein 
lysis buffer (see 4.1.5). Concentrations of proteins were measured by Quant-iT protein assay 
kit (Invitrogen, Carlsbad, CA, USA). Proteins were denatured in a 5% SDS solution for 10 
min at 95°C. 20-30 g proteins were loaded and separated by SDS-PAGE (12%). After the 
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transfer to a nitrocellulose membrane, proteins were blocked in PBST (see 4.1.5) with 5% 
non-fat milk overnight at 4°C. The membrane containing proteins were washed in PBST and 
incubated with primary antibodies at RT for 1.5 hour.  After washing, proteins were incubated 
with secondary HRP-labeled antibody at RT for 1h. The membrane was washed with PBST, 
then incubated with luminescent substrate ECL (Amersham, Piscataway, NJ) and visualized 
by the OPTIMAX film-developing machine (PROTEC Medizintechnik, Oberstenfeld, 
Germany). Western blot bands were quantified by imageJ software. 
4.2.2.6 Proteomics 
Proteomics was performed in collaboration with Stefan Lichtenthaler’s group at the German 
Center for Neurodegenerative Diseases (DZNE) in Munich. Samples are prepared as 
described before (Wisniewski et al., 2009b). Briefly, 20x106 BMDCs were lysed and sonified 
in a sonication bath. The lysates were then centrifuged at 13,000 rpm for 5 min. The 
supernatant containing proteins were collected and digested using the FASP method as 
described before (Wisniewski et al., 2009b). Protein peptides were fractionated into three 
fractions using strong anion exchange in a pipet-tip based format as described before 
(Wisniewski et al., 2009a). Protein fractions were desalted using home made C18 STAGE tips 
(Rappsilber et al., 2007). 3 μg of the fractionated peptides were injected per run. Samples were 
analyzed on an easy nLC liquid chromatography system and on the LTQ Velos Orbitrap Pro 
mass spectrometer using a homemade 15 cm column and 2 h gradients. 5 biological replicates 
with 2 technical replicates were analyzed using Cre control and RhoA-ko samples. The 
obtained raw data were subjected to label free quantitation using the freely available 
MaxQuant software. Statistical analysis was carried out in Perseus software. Only proteins 
with 2 or more unique peptides in at least 3 out of 5 biological were considered as identified 
proteins. 
4.3 Statistical analysis 
Statistical differences between the experimental groups were determined by Student’s two-
tailed t-test. Probabilities < 0.05 were considered to be significant. 
 
 28 
5. RESULTS 
5.1 Verification of RhoA knock out efficiency in DCs 
In order to explore RhoA functions in DCs, we generated DC-specific RhoA-ko mice by 
crossing mice carrying loxP-flanked RhoA alleles (RhoAfl/fl) with CD11c-Cre mice (Fig. 3A). 
The Cre recombinase is selectively expressed in CD11c-positive DCs under the control of 
CD11c promoter (Fig. 3A). Cre will bind to LoxP sites and cut off exon 3 of RhoA gene 
specifically in DCs, leading to RhoA deletion (Fig. 3A). To verify the RhoA ko efficiency, a 
qPCR was performed to detect RhoA mRNA levels in BMDCs and ex vivo isolated spleen 
DCs. We found that RhoA mRNA was significantly decreased in both BMDCs and spleen 
DCs, however we were still able to detect low levels of residual RhoA mRNA (Fig. 3B). To 
further confirm RhoA knock out efficiency on protein level, we performed a Western blot by 
using total protein extracted from BMDCs and spleen DCs isolated via MACS. As shown in 
Figure 3C, RhoA protein has been effectively deleted from both RhoA-ko BMDCs and spleen 
DCs. Since the purity of CD11c+ BMDCs is around 90%, the observed RhoA mRNA and 
protein residual may derive from non-DC cells, such as CD11clow monocytes and 
macrophages.  
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Figure 3. Generation and verification of RhoA ko in DCs. 
(A) Cre is expressed specifically in DCs under the control of CD11c promoter. The exon 3 of RhoA allele is 
flanked with LoxP sequence. Upon Cre–mediated recombination, the RhoA exon 3 between two LoxP sites is 
excised, resulting in RhoA inactivation. (B) RhoA mRNA levels were determined by qPCR in BMDCs and 
spleen DCs. Relative RhoA mRNA levels were obtained by normalization to HPRT mRNA levels. Bars represent 
mean ± SEM (n=3). (C) RhoA protein expression in RhoA-ko BMDCs and spleen DCs were detected by Western 
blot. β-actin served as a protein loading control. Figures show representative data of one out of at least three 
experiments with similar outcome. 
5.2 RhoA deletion results in reduced numbers of cDCs in spleen 
To provide insights into the role of RhoA in DCs, we first characterized DC populations in 
RhoA-ko mice. In spleen, cDCs were identified as CD11c+MHC-II+ cells, which significantly 
decreased in RhoA-ko mice (Fig. 4A). The percentages of cDC significantly reduced in RhoA-
ko mice compared to Cre controls (Fig. 4A). Further analyses of DC subsets showed that 
CD11b+ cDCs had a more severe reduction in total cell numbers compared to CD8+ cDCs (Fig. 
4B). Recently, splenic CD11b+ DCs have been shown to consist of two distinct Esamhi and 
Esamlo populations (Lewis et al., 2011). CD11b+Esamhi DCs are pre-cDC-derived, and 
dependent on Notch2 and LTβR signaling with a higher turnover rate (Lewis et al., 2011; 
Wang et al., 2005; Yi and Cyster, 2013). CD11b+Esamlo DCs are Notch2 independent and 
have a monocyte-derived origin (Lewis et al., 2011; Wang et al., 2005; Yi and Cyster, 2013). 
So we also analyzed Esamhi and Esamlo DC subsets within CD11b+ DC compartment. Esamhi 
DCs dramatically decreased in spleens of RhoA-ko mice both in percentage and total cell 
numbers (Fig. 4A,B). However, the total number of Esamlo DCs remained unaltered in RhoA-
ko mice (Fig. 4A,B). In addition, we also found the expression of CD4 strongly reduced in 
CD11b+ DCs showing a similar effect as Esam marker by RhoA deletion (Fig. 4A). Our 
results indicate that RhoA deletion causes significant decrease in number of CD8+ and 
CD11b+Esamhi cDCs but not in CD11b+Esamlo cDCs.  
Previous studies have shown that CD8+ cDCs were located mostly in T cell zones (Dudziak et 
al., 2007), while CD11b+ cDCs were preferentially located in the red pulp of spleen (Yi and 
Cyster, 2013). Therefore, we wondered whether the positioning of those two DC subsets was 
altered by RhoA deletion. To test that, we performed histological analyses and found that the 
main structure of spleens in RhoA-ko mice remained intact, with normal T and B cell zones 
(Fig. 4C). Both CD8+ and CD11b+ cDCs were present in their proper location in spleens of 
RhoA-ko mice (Fig. 4C). However, the total numbers of both DC subsets were markedly 
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reduced in RhoA-ko mice (Fig. 4C), consistent with the finding from flow cytometry (Fig. 
4A,B). This result indicates that deletion of RhoA did not affect the positioning of cDC, but 
caused significantly decreased numbers of cDC in spleen. 
 
Figure 4. RhoA is essential for the homeostasis of DCs in spleen. 
(A) cDCs are identified as CD11c+MHC-II+ in spleen. cDCs can be separated into CD8+ and CD11b+ DC subsets.  
Expression of Esam and CD4 was further analyzed in CD11b+ DC compartment. The percentages represent mean 
± SEM (n=3). (B) Bar graphs show total cell numbers of cDC and different DC subsets (n=3).  (C) Histology 
staining identified B cells (B220+, blue), CD8+ T cells (CD8+, green), marginal zone macrophages (MOMA+, 
white) and cDCs (CD11c+, red) in the spleen of Cre control and RhoA-ko mice. Figures show representative data 
of one out of at least six experiments with similar outcome. 
5.3 RhoA deletion results in number reduction of cDCs in lymph nodes and 
thymus 
In lymph nodes, both migratory (MHC-II high) and resident (MHC-II intermediate) cDCs 
were markedly decreased in RhoA-ko mice (Fig. 5A). Resident DCs can be divided into CD8+ 
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and CD11b+ DC subsets.  The total number of resident CD8+ DC was significantly reduced, 
while CD11b+ DCs remained largely unaltered in RhoA-ko mice (Fig. 5A). Migratory DCs 
can be divided into three subsets CD103+CD11b-, CD103-CD11b+ and CD103-CD11b- DCs. 
In RhoA-ko mice, all of these migratory DC subsets were significantly reduced in total 
number (Fig. 5A). In thymus, cDCs are identified as CD45RA-CD11c+, while pDCs are 
identified as CD45RA+CD11cint (Onai et al., 2013)(Fig. 5B). As shown in Figure 5B, the total 
number of cDC was significantly decreased in thymus of RhoA-ko mice, while pDC remained 
unaffected by RhoA deficiency. Our results indicate that cDCs significantly decreased also in 
lymph nodes and thymus of RhoA-ko mice. 
 
Figure 5. DC reduction in lymph nodes and thymus. 
(A) Inguinal, axillary and brachial lymph nodes were pooled and analyzed for DC populations based on 
expression of CD11c and MHC-II. Resident DCs (MHC-II intermediate) were further analyzed for expression of 
CD8 and CD11b. Migratory DCs (MHC-II high) were analyzed for expression of CD103 and CD11b. 
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Percentages represent mean ± SEM (n=3). Bar graphs show the total cell number of DCs and DC subsets in 
lymph nodes (n=3). (B) pDCs and cDCs were identified as CD11cintCD45RA+ and CD11c+CD45RA- respectively 
in thymus. Total cell number of pDCs and cDCs in thymus were shown in bar graphs (n=3). Figures show 
representative data of one out of at least three experiments with similar outcome. 
5.4 RhoA deletion exclusively affects CD11chi cells in lymphoid organs 
Certain levels of CD11c expression has been found on monocytes, macrophages and activated 
T cells (Merad et al., 2013). In order to find out if other cells are affected by CD11c-Cre- 
mediated RhoA deletion, pDCs (CD45RA+PDCA1+), monocytes (Ly6C+CD11b+), 
macrophages (B220-F4/80+) were analyzed in lymph nodes and spleen. As shown in Figure 
6A, monocytes and macrophages were unaltered in lymph nodes and spleens of RhoA-ko mice. 
Numbers of CD11clow pDCs were reduced to some extent (Fig. 6A). Furthermore, CD4+ T 
cells, CD8+ T cells and B cells in spleen were also analyzed by flow cytometry. As shown in 
Figure 6B, numbers of CD4+ T cells and B cells remained unchanged, while CD8+ T cells 
were slightly reduced in numbers (Fig. 6B). It is known that CD8+ T cells partially do express 
CD11c-driven transgenes (Lin et al., 2003). These data indicate that RhoA deficiency mainly 
causes reduction in the number of cDCs, which express high level of CD11c.  
 
Figure 6. RhoA ko phenotype is restrained in cDCs in lymphoid organs. 
(A) pDCs (PDCA-1+CD45RA+), monocytes (CD11b+Ly6c+) and macrophages (F4/80+B220-) were identified in 
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lymph nodes (as in Fig. 5A) and spleen. The total cell numbers of those cell types were shown in bar graphs 
(n=3). (B) CD4+ T cells, CD8+ T cells and B cells are identified in the spleen of Cre control and RhoA-ko mice. 
Bar graphs show total cell numbers of CD4+ T cells, CD8+ T cells and B cells in spleen (n=3). Figures show 
representative data of one out of at least three experiments with similar outcome. 
5.5 RhoA deficiency does not affect the seeding of DC precursors into spleen 
cDCs are generated by their immediate precursors called pre-cDCs, which originate from 
hematopoietic stem cells in the BM (Liu et al., 2009; Naik et al., 2006; Satpathy et al., 2012). 
To test if the observed DC reduction was caused by defects of pre-cDCs, we analyzed 
frequencies of pre-cDC in BM and spleen. As shown in Fig. 7A, pre-cDCs are identified as 
Lin-CD11c+MHC-II-CD43+Sirpαint cells in BM and spleen. Pre-cDCs represent around 0.25% 
of BM cells and 0.18% of spleen cells (Fig. 7A). RhoA deficiency did not affect the frequency 
and total number of pre-cDCs in BM and spleen (Fig. 7A). As pre-cDCs express only low 
levels of CD11c, it was necessary to confirm if RhoA gene has been effectively deleted in 
RhoA-ko pre-cDCs. A qPCR was performed to examine relative RhoA mRNA transcripts in 
pre-cDCs. Pre-cDCs from BM still contained normal levels of RhoA mRNA (Fig. 7B). 
Interestingly, after seeding in spleen, pre-cDCs showed significantly reduced RhoA mRNA 
(Fig. 7B), suggesting the migration process might provide essential time for deletion of RhoA 
gene. However, the frequency and total number of pre-cDCs still remained unaffected by 
RhoA deficiency in spleen (Fig. 7A). These results suggest that RhoA deficiency does not 
affect the seeding of pre-cDC into spleen. 
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Figure 7. Deletion of RhoA does not affect the seeding of pre-cDCs into spleen 
(A) Pre-cDCs are recognized as Lin-CD11c+MHC-II-CD43+Sirpαint in BM and spleen. Bar graphs show the 
percentages and total numbers of pre-cDCs in BM and spleen (n=3). Lin: CD3/CD19/NK1.1/B220. (B) RhoA 
mRNA level in pre-cDC was determined by qPCR. Bar graph shows RhoA mRNA transcript in pre-cDCs sorted 
from BM culture supplemented with Flt3L or directly from spleen (n=3). Figures show representative data of one 
out of three experiments with similar outcome. 
5.6 The generation of cDCs from progenitors is not affected in RhoA-ko 
mice 
Since the frequency and total cell numbers of pre-cDCs are not affected, we further asked if 
the observed cDC reduction was due to defects in the generation of cDCs from their 
progenitors in RhoA-ko mice. We next analyzed the potential of DC-precursors generating 
cDCs in vitro.  Pro-DC (Lin-CD11c-CD43+Ly6C-, pre-cDC precursors) and pre-cDCs (Lin-
CD11c+MHC-II-CD43+Sirpαint) were isolated from BM culture supplemented with Flt3L or 
directly from spleen as described previously (Naik et al., 2006; Naik et al., 2007), and cultured 
in vitro to monitor their potential of giving rise to cDCs (Fig. 8). Pro-DCs (CD11c-MHC-II-) 
first develop into CD11c+MHC-II- pre-cDCs, and then fully differentiate into CD11c+MHC-II+ 
cDCs (Fig. 8). These in vitro culture analyses showed that pro-DCs from BM of RhoA-ko 
mice were able to differentiate into pre-cDCs and cDCs normally (Fig. 8, upper panels). Pre-
cDCs, either isolated from BM or spleen of RhoA-ko mice, could also differentiate normally 
into cDCs in vitro (Fig. 8, lower panels). This result suggests that the generation of cDCs from 
DC precursors is not affected in RhoA-ko mice (Fig. 8). 
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Figure 8. The generation of cDCs from progenitors is not affected in RhoA-ko mice.  
Pro-DCs (Lin-CD11c-CD43+Ly6C-) and pre-cDCs (Lin-CD11c+MHC-II-CD43+Sirpαint) were sorted from BM 
culture supplemented with Flt3L; Meanwhile pre-cDCs were also sorted directly from spleen. Then, pro-DCs and 
pre-cDCs were re-cultured in vitro for 3-5 days. The expression of CD11c and MHC-II was monitored over days 
by flow cytometry. Bar graphs show the generation of pre-cDC or cDC from pro-DC or pre-cDC (n=3). Figures 
show representative data of one out of three experiments with similar outcome. 
5.7 cDC reduction is DC-intrinsic in RhoA-ko mice 
To further investigate whether the cDC reduction is a cell intrinsic effect, or rather caused by 
secondary factors in spleens of RhoA-ko mice, we generated BM-chimeras. To this end, we 
transferred a 50:50 mixture of CD45.1+ CD11c-Cre control and CD45.2+ RhoA-ko BM cells 
was into lethally irradiated CD45.2+ B6 mice. As control, we also transferred 100% CD45.1+ 
BM cells into irradiated CD45.2+ B6 mice.  These mice were analyzed alongside with the 
experimental groups, and we found less than 1% of total cells derived from host BM, 
suggesting a near-complete eradication of host BM (data not shown).  After 8 weeks, we 
analyzed DC reconstitution in these mixed BM chimeras. RhoA-deficient cDCs reconstituted 
only 13% of the cDC-pool in spleens of mixed BM chimeras (Fig. 9A). Compared to CD11c-
Cre control, RhoA-deficient CD8+ and CD11b+Esamhi DCs were dramatically decreased in 
total cell number (Fig. 9B). In contrast, CD11b+Esamlo DCs showed only a slight number 
decrease (Fig. 9B) confirming the normal homeostasis independent of RhoA. Furthermore, 
expression of CD4 was significantly reduced in RhoA-ko-derived CD11b+ cDCs (Fig. 9A), 
similar as observed in steady state RhoA-ko mice (Fig. 4A). In mixed BM chimeras, a distinct 
population of CD8-CD11b- cDCs became more apparent (Fig. 9A) compared to frequencies in 
the non-competitive situation (Fig. 4A), which are the natural immature stages of CD8+ DC 
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and CD11b+ (Lewis et al., 2011). However, these RhoA-deficient CD8-CD11b- cDCs were 
also markedly reduced in total numbers compare to Cre controls (Fig. 9B). As internal controls, 
B and T cells were also analyzed in mixed BM chimeras. RhoA-deficient BM cells generated 
B and T cells with slightly higher efficiency compared to CD11c-Cre-derived BM cells (Fig. 
9B). Taken together, these results indicate that cDC reduction is cell intrinsically due to RhoA 
deficiency and not caused by secondary effects.  
 
Figure 9. DC reduction caused by RhoA deficiency is cell intrinsic. 
(A) Irradiated B6 mice (CD45.2) were reconstituted with a BM mixture equally from CD11c-Cre control 
(CD45.1) and RhoA-ko (CD45.2) mice. After 8 weeks of reconstitution, cDC and DC subsets were characterized 
by flow cytometry. Cre-control-derived-cDCs were gated on CD45.2-CD11c+, while RhoA-ko-derived cDCs 
were gated on CD45.2+CD11c+. (B) Bar graph shows the ratio of CD45.2+ RhoA-ko-derived cells vs. CD45.1+ 
CD11c-Cre-derived cells. The ratio of 1 represents equal contribution of CD45.1+ and CD45.2+ cells. Bars 
represent mean ± SEM for three mice. Figure shows representative data of one out of four experiments with 
similar outcome. 
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5.8 RhoA deficiency indirectly causes increased rate of Ki67+ proliferating 
cDCs in spleen. 
DCs were initially thought as non-dividing cells, until recent studies showed that about 5% of 
cDCs in the spleen were dividing at any time (Kabashima et al., 2005; Liu et al., 2007). 
Therefore, cDC in situ proliferation is very important for maintaining homeostatic cDC 
numbers in spleen. So we wondered if cDC in situ proliferation was affected by RhoA 
deficiency. In order to test DC proliferation, we stained spleen cDCs with nuclear dye DAPI 
and an antibody against proliferation marker Ki67 (Fig. 10). As described previously, about 
5% of spleen cDCs were proliferating (DAPI+Ki67+) in CD11c-Cre control mice (Fig. 10A). 
However, cDC proliferation rate increased more than two-fold in spleens of RhoA-ko mice 
(11.7%, Fig. 10A). To determine if this enhanced proliferation was caused by RhoA 
deficiency, or rather by altered environmental effects, we further analyzed cDC proliferation 
in mixed BM-chimeras as described above (Fig. 9). In this competitive situation, we were able 
to analyze proliferation of control- and RhoA-ko-derived cDCs in the same microenvironment. 
Here, the proliferation rate of RhoA-ko-derived cDCs significantly decreased to around 5% 
(Fig. 10B), as compared to non-chimeras (Fig. 10A, 11.7%). Both, Cre control- and RhoA-ko-
derived cDCs exhibited the same normal proliferation rate, suggesting that the increased cDC 
proliferation in RhoA-ko mice (Fig. 10A) was not caused by RhoA deficiency itself, but rather 
by secondary effects. Then we wondered which secondary effects might cause enhanced 
proliferation of cDCs in spleens of RhoA-ko mice. It has been reported that constitutive 
ablation of cDC led to significantly elevated serum levels of Flt3L, which in turn caused 
myeloproliferation (Birnberg et al., 2008). Since Flt3L plays an important role in promoting 
DC proliferation (Waskow et al., 2008), we therefore measured serum levels of Flt3L. In 
RhoA-ko mice, serum levels of Flt3L were significantly elevated compared to control mice 
(Fig. 10C). These findings suggest that RhoA is not required for proliferation of cDCs. 
However, the reduction of cDC numbers leads to elevated levels of Flt3L in serum, which in 
turn induces enhanced cDC proliferation in RhoA-ko mice. 
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Figure 10. RhoA deficiency causes enhanced proliferation of cDCs due to increased serum Flt3L. 
(A) The proliferating cDCs (CD11c+MHC-II+) were detected as Ki67+ in S-G2-M phase (DAPIhi). Isotype 
antibody was used as negative control for Ki67 staining. The percentages represent mean ± SEM for three mice.  
(B) Proliferation rates of Cre-control (CD45.1+) and RhoA-ko (CD45.2+) derived cDCs was measured in 50:50 
mixed BM chimeras by flow cytometry. The percentages represent mean ± SEM for three mice.  (C) Serum 
levels of Flt3L of Cre control and RhoA-ko mice were determined via ELISA (n=6). Figures show representative 
data from one out of three experiments with similar outcome. 
5.9 RhoA controls cytokinesis of DCs 
As reported previously, RhoA controls cytokinesis by regulation of cortical contractility and 
cleavage furrow formation during proliferation (Olson et al., 1995; Sahai and Marshall, 2002). 
We next examined if RhoA deficiency altered the distribution of DCs at different stages of the 
cell division cycle (G1, S and G2/M phase). We first analyzed cell cycle in BMDCs and found 
that RhoA-deficient BMDCs accumulated in S and G2/M-phases (Fig. 11A). In addition, 
RhoA deficiency caused increased polyploid cells in BMDCs (Fig. 11A). This finding is 
consistent with previous studies in RhoA deficient keratinocytes (Jackson et al., 2011) and 
fibroblasts (Melendez et al., 2011). Similarly, spleen cDCs also showed accumulated cells in S 
and G2/M-phases in RhoA-ko mice, but polynuclear cells in vivo were lacking (Fig. 11A). 
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Furthermore, to test if such accumulation of spleen cDC in S and G2/M-phases was actually 
caused by deletion of RhoA or secondary effects, we generated 50:50 mixed BM-chimeras as 
described above. RhoA-ko-derived cDCs showed an accumulation of cDC in S and G2/M-
phases compared to Cre control (Fig. 11B), indicating a direct effect of RhoA deletion. These 
data suggest that RhoA regulates cell cycle progression in cDC. To further understand at 
which phase that RhoA-ko DCs were arrested, we performed mitosis analysis using 
imagestream (Fig. 11C, D). During mitosis, BMDCs accumulated in the anaphase, while ex 
vivo isolated spleen cDC accumulated in both anaphase and telophase (Fig. 11C), which 
normally coincide with cytokinesis (Shuster and Burgess, 1999). Taken together, these results 
suggest that RhoA is critical for regulating cytokinesis in DCs. 
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Figure 11. RhoA deficiency causes cytokinesis failure.  
(A) Cell cycle of BMDCs and spleen DCs was analyzed by DAPI staining of nuclei. Representative histograms 
show the cells in different phases (G1, S, G2-M and polyploidy) during cell cycle. Bar graphs indicate the 
percentages of BMDCs and spleen DCs in different phases (n=3). (B) Cell cycle of spleen DCs in 50:50 mixed 
BM chimeras was analyzed by flow cytometry. Bar graphs indicate the percentages of cre-control- and RhoA-ko-
derived spleen DCs in different phases (n=3). (C) Representative images of BMDCs in different phases of mitosis 
were selected at random from over 3,000 images by imagestream AMNIS. Bar graph shows the percentages of 
BMDCs in different phases during mitosis (n=3). (D) Representative images of spleen DCs in different phases of 
mitosis were selected at random from over 1,000 images. Bar graph shows the percentages of spleen DCs in 
different phases during mitosis (n=3). Figures show representative data from one out of three experiments with 
similar outcome. 
5.10 RhoA-deficient cDCs show decreased long-term survival 
To estimate the influence of RhoA deletion on cDC turnover rates, we performed in vivo BrdU 
pulse-chase experiments (Fig. 12A,B). After three days BrdU pulse, cDCs from RhoA-ko 
mice exhibited a significant higher BrdU-incorporation rate as compared to cDCs from control 
mice (Fig. 12A). After withdrawal of BrdU, the percentage of BrdU+ cDCs started to decline 
over time (Fig. 12A). RhoA-deficient cDCs showed a much faster decline of BrdU-
incorporation compared to Cre control (day 9, 12, Fig. 12A). Further analysis of DC subsets 
showed that both CD8+ and CD11b+ cDCs presented a much faster decline of BrdU-
incorporation in RhoA-ko mice (Fig. 12A), suggesting that RhoA-deficient cDCs had a shorter 
half-life. In order to find out if the reduced cDC turnover rate in RhoA-ko mice is caused 
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intrinsically by RhoA deletion, we also analyzed cDC turnover in 50:50 mixed BM chimeras 
(Fig. 12B).  In this competitive situation, RhoA-deficient cDCs showed same BrdU-
incorporation as Cre control during 3 days pulse phase (Fig. 12B), indicating normal 
proliferative behavior despite absence of RhoA, which was also determined above by Ki67 
staining in mixed BM chimeras (Fig. 10B). Furthermore, RhoA-deficient CD11b+ cDCs 
showed faster decline of BrdU-incorporation at day 9 and 12, whereas CD8+ cDCs showed 
faster decline only at day 12 (Fig. 12B), suggesting CD11b+ cDC are more affected by RhoA 
deficiency than CD8+ cDC. Taken together, these results indicate that RhoA deficiency 
directly leads to reduced half-life of cDC. 
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Figure 12. RhoA deficiency results in shorter turnover rate of cDC in vivo. 
(A) Control and RhoA-ko mice received in vivo BrdU-labeling for 3 days (pulse phase), then followed by 9 days 
of BrdU-free chase phase. The frequency of BrdU+ spleen cDCs, CD8+ and CD11b+ DC subsets was examined 
by flow cytometry at day 3, 6, 9 and 12. The percentages of BrdU+ DC at each time point within total cDC, CD8+ 
DC or CD11b+ DC are displayed in line graphs (n=3). (B) 12 days of BrdU pulse-chase experiment was also 
performed in 50:50 mixed BM chimeras as in fig. 12A (n=3). Line graphs show BrdU kinetics of Cre-control 
(CD45.1+) and RhoA-ko (CD45.2+) derived total cDCs, CD8+ and CD11b+ cDCs in spleen. Figure shows 
representative data from one out of 3 experiments with similar outcome. 
5.11 RhoA deficiency causes increased apoptosis of cDC 
Since BrdU-labeling in vivo suggests a shorter half-life in RhoA-deficient cDCs, we next 
performed TUNEL assays to test if RhoA-deficient cDCs had increased apoptosis in spleen. 
As shown in Figure 13A (upper panel), RhoA-ko mice exhibited two-fold more TUNEL-
positive cDCs in spleen compared to control mice. In addition, we found that most of 
apoptotic cDCs occurred during G1 phase of cell cycle (DAPI-, Fig. 13A). To confirm that the 
increased apoptosis is directly due to RhoA-deletion in DCs, we also performed TUNEL 
assays in mixed BM chimeras. In the competitive situation, RhoA-ko-derived cDCs showed 
even more severe increased of TUNEL-positive cells, as compared to Cre-control-derived 
cDCs (Fig. 13A, lower panel), suggesting RhoA intrinsically controlled cDC survival. In order 
to further confirm that RhoA-deficiency causes increased apoptosis in spleen cDCs, we 
performed Annexin-V staining combined with viability dye 7-AAD to detect apoptotic spleen 
cDCs in steady state. Compared to Cre control mice, the percentage of apoptotic 
CD11b+Esamhi cDCs (Annexin-V+) was significantly increased, while CD8+ and 
CD11b+Esamlo cDCs did not show significant alteration in RhoA-ko mice (Fig. 13B). As 
controls we also analyzed Annexin-V positive MHC-II+CD11c- cells (including B cells) and 
CD8+CD11c- cells (including CD8+ T cells), which did not show increased apoptotic cells (Fig. 
13B). Furthermore, we also monitored BMDC survival in vitro by removing DC growth factor 
GM-CSF. Upon GM-CSF removal, RhoA-deficient BMDCs showed significantly impaired 
survival kinetics compared to Cre control (Fig. 13C), which was consistent with in vivo 
findings (Fig. 13A, B). These results indicate that RhoA is essential for maintaining the cDC-
survival.  
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Figure 13. RhoA deficiency leads to increased apoptotic DCs in vivo and in vitro.  
(A) cDCs were first gated on CD11c+MHC-II+ in spleen, then apoptotic cDCs were detected by TUNEL assay in 
steady state and mixed BM chimeras. Cells were not treated with TdT enzyme as negative control. Combined 
with DAPI staining, apoptotic cDCs in different stages of cell cycle can be identified. Bar graphs show 
percentages of total TUNEL+ cDCs in spleen (n=3). (B) Annexin-V and 7-AAD were used for detecting 
apoptotic CD8+, Esamhi and Esamlo DC subsets in spleens of Cre control and RhoA-ko mice in steady state. Bar 
graph shows the percentages of total Annexin-V+ DC subsets as well as B cells and CD8+ T cells (n=3). (C) 
BMDC survival kinetic was monitored over 4 days after removal of GM-CSF (n=3). Figure shows representative 
data from one out of 3 experiments with similar outcome. 
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5.12 Proteome analysis of RhoA-deficient DCs 
As we already know that RhoA controls cDC-survival based on the results above, and 
wondered which signaling pathway was involved in RhoA-regulated cDC survival. Therefore, 
a proteome analysis was performed in collaboration with Stephan Lichtenthaler’s group at the 
German Center for Neurodegenerative Diseases (DZNE) to investigate proteins that were 
differentially expressed between Cre-control and RhoA-ko BMDCs. Dr. Bastian Dislich 
(DZNE) performed the protein analysis as well as bioinformatics. A total of 2699 proteins 
could be identified with at least 2 unique peptides for each protein (Fig. 14A). Only the 
proteins with more than 3 fold changes are considered as significantly up- or down-regulated 
in RhoA-ko BMDCs. Therefore, we identified 54 up-regulated and 39 down-regulated 
proteins, which are listed in table 3 (7. Appendix). According to Gene Ontology (GO) terms, 
some of those protein play roles in regulating cell cycle progression (GO:0022402) and 
programmed cell death (GO:0043067), which are displayed as green and red respectively in 
volcano plots (Fig. 14A).   Among those, a pro-survival protein phophoinositide 3-kinase 
gamma (PI3Kγ) was markedly down-regulated in RhoA-deficient BMDCs (Fig. 14A). 
Previous studies have shown that PI3Kγ can promote cell survival through phosphorylation of 
its downstream effector Akt (Comerford et al., 2012; Johnson et al., 2007). Active Akt inhibits 
the pro-apoptotic function of Bcl-2-associated death promoter (BAD) by phosphorylating (She 
et al., 2005). Therefore, we hypothesized that RhoA deletion caused down-regulated PI3Kγ, 
which in turn led to increased apoptosis due to inefficient phosphorylation of Akt and BAD in 
DCs. To prove our hypothesis, we performed Western blot to determine protein levels of 
PI3Kγ, Akt and BAD, as well as phosphorylation of Akt and BAD in BMDCs and spleen 
cDCs isolated by MACS. First, we verified that RhoA protein has been effectively knocked 
out in both RhoA-ko BMDCs and spleen cDCs (Fig. 14B). Western blot data showed that 
PI3Kγ were significantly reduced in both RhoA-ko BMDCs and spleen cDCs (Fig. 14B), 
confirming the proteomics data. The total protein levels of Akt and BAD remained same 
between Cre control and RhoA-ko (Fig. 14B).  However, phosphorylation of Akt and BAD 
significantly impaired in RhoA-ko BMDCs and spleen cDCs, possibly due to down-regulation 
of PI3Kγ. These results indicate that the pro-survival PI3Kγ/Akt/BAD signaling pathway is 
inhibited in RhoA-deficient DCs, which might be responsible for the increased cDC apoptosis. 
In addition, to better understand how RhoA regulates the expression of PI3Kγ, we also 
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analyzed transcripts of PI3Kγ in cDCs. And we found that mRNA levels of PI3Kγ were 
significantly decreased in RhoA-ko cDCs (Fig14. C), suggesting RhoA might regulate the 
transcription of PI3Kγ in DCs. Therefore, deletion of RhoA leads to reduced PI3Kγ mRNA 
transcription, which then results in reduced protein levels of PI3Kγ. However, the exact 
mechanism how RhoA controls expression of PI3Kγ is still unknown.  
It has been reported that RhoA deletion caused increase of HPCs death through programmed 
necrosis, characterized by up-regulated transcription of necrosis-related genes (Zhou et al., 
2013). In order clarify if increased cDC cell death in RhoA-ko mice is rather caused by 
apoptosis or necrosis, we analyzed mRNA levels of some critical necrosis-induced genes in 
spleen cDCs, such as tumor necrosis factor alpha (TNF-α), TNFR1, Ripk1, Ripk3, Fth1 and 
Glud1 (Vandenabeele et al., 2010; Zhou et al., 2013). Compared to Cre control, none of those 
genes showed significant alteration, except TNF-α, which was rather down-regulated in 
RhoA-ko spleen cDCs (Fig. 14D). This result suggests that increased cDC death due to RhoA 
deficiency is not caused by necrosis. Taken together, our findings indicate that RhoA 
maintains cDC survival through regulating PI3Kγ/Akt/BAD signaling pathway (Fig. 14E). 
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Figure 14. RhoA promotes DC survival through PI3K/Akt/BAD pathway.  
(A) BMDCs from Cre control and RhoA-ko mice were used for proteome analysis. A total of 2699 proteins were 
detected as shown in volcano plots. Proteins that are up- or down-regulated more than 3 fold in the RhoA-ko 
BMDCs are considered as significantly altered. Among those proteins, cell survival-related proteins (red color) 
and cell cycle-related proteins (green color) are indicated. (B) The total amount of PI3Kγ, Akt and BAD, as well 
as phosphorylation of Akt and BAD was determined by Western blot. Bar graphs show quantification of Western 
blot bands done by ImageJ software. (C) The mRNA of PI3Kγ was determined in spleen cDCs by qPCR. (D) The 
mRNA of necrosis-related genes in spleen cDCs was determined by qPCR. (E) Sketch of RhoA/PI3K/Akt/BAD 
signaling pathway regulating DC survival. RhoA-deletion caused down-regulation of PI3Kγ, and inefficient 
phosphorylation of Akt and BAD resulting in cDC apoptosis. 
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6. DISCUSSION 
6.1 RhoA and DC homeostasis 
RhoA, Cdc42 and Rac1 are the best-studied members in small Rho GTPase family, which 
regulate multiple cell functions including cytoskeleton organization, migration, survival and 
gene expression (Jaffe and Hall, 2005; Tybulewicz and Henderson, 2009). Previous studies 
have shown that RhoA plays important roles in regulating morphology, antigen presentation 
and migration of DCs, by applying C3 transferase, overexpression of dominant-negative 
mutants or inhibiting the RhoA activator Arhgef5 (Kobayashi et al., 2001; Shurin et al., 2005; 
Wang et al., 2009). Furthermore, studies using SWAP-70 (an activator of RhoA) deficient 
mice have indirectly shown that RhoA regulated motility and endocytosis of DCs (Ocana-
Morgner et al., 2011), as well as the surface localization of MHC-II in DCs (Ocana-Morgner 
et al., 2009). However, RhoA functions in DCs are still largely unknown. In this study, we 
used DC-specific RhoA-ko mouse model to study RhoA functions in DCs, and found that 
RhoA was crucial for maintaining a defined numbers of cDCs in vivo through promoting DC 
survival. 
DCs play a crucial role in regulating both immunity and tolerance in vivo. Therefore, it is 
important to understand how DC homeostasis is maintained in lymphoid organs. The 
following mechanisms are involved in maintaining suitable numbers of cDCs in lymphoid 
organs: constant replenishment by precursors, in situ proliferation and apoptosis (Liu et al., 
2007). RhoA deficiency caused dramatic reduction in number of total cDCs in lymph nodes, 
spleen and thymus (Fig. 4A, Fig. 5A,B). In spleen, CD8+ DCs and CD11b+Esamhi DCs were 
significantly decreased in total cell number, whereas CD11b+Esamlo DCs largely remained 
unaltered (Fig. 4B). Unlike other DC subsets, which are derived from pre-cDCs, 
CD11b+Esamlo DCs are most likely derived from monocytes or earlier monocytic precursors 
(Klebanoff et al., 2013; Lewis et al., 2011). Therefore, we speculated that CD11b+Esamlo DCs 
probably received constant replenishment from monocytes or some earlier monocytic 
precursors, which compensated the loss of this DC subset in steady state. However, the precise 
origin of CD11b+Esamlo DCs is still unknown, and needs to be defined.  
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6.2 RhoA and DC proliferation 
It has been reported earlier that inhibition of RhoA caused impaired proliferation of breast 
cancer cells (Pille et al., 2005). So we wondered if RhoA deficiency caused impaired 
proliferation of DC, which could lead to cDC reduction. In contrast, we found that the rate of 
proliferating cDCs was not impaired, but rather increased more than two-fold in spleens of 
RhoA-ko mice, compared to Cre control mice (Fig. 10A).  However, further analysis in mixed 
BM chimeric mice showed that RhoA-deficient cDCs had the same proliferation rate of 5% as 
Cre-control cDCs (Fig. 10B), suggesting that the enhanced DC proliferation in RhoA-ko mice 
was rather caused by environmental factors, but not directly related to RhoA-deletion. To find 
out which environmental factors altered in RhoA-ko mice causing enhanced cDC proliferation, 
we first analyzed Flt3L. Its receptor, Flt3, is expressed on DCs, but not on other cells such as 
B cells, T cells, NK cells and monocytes (Karsunky et al., 2003). Therefore, cDCs are 
considered as major "consumers" of Flt3L among peripheral mature hematopoietic cells 
(Karsunky et al., 2003). Loss of cDC might cause accumulation of Flt3L, resulting in 
abnormally high concentrations of this growth factor, which in turn might trigger increased 
cDC proliferation (Karsunky et al., 2003). In the CD11c-DTR mouse model, complete 
ablation of cDC led to a 3-fold increase of Flt3L in serum and enhanced proliferation in vivo 
(Birnberg et al., 2008). In RhoA-ko mice, the numbers of cDC were reduced around 2-fold in 
spleens, leading to 1.5-fold increased Flt3 serum-concentration (Fig. 10C). The increased 
levels of Flt3L promoted cDC proliferation, which to some extent compensated the loss of 
cDCs caused by RhoA deletion. This increased proliferation was abrogated in mixed BM-
chimeras, where competitor wt DCs could fill up the DC-pool to normal numbers. This data 
suggest that altered numbers of cDCs change the balance of environmental effectors such as 
Flt3L, which in turn affects cDC proliferation. Similarly, RhoA deficiency in HSC also led to 
significant increase in proliferation of HSCs, which might be a secondary effect due to acute 
hematopoietic stress (Zhou et al., 2013). In addition, it has been shown that B cell proliferation 
was not affected by RhoA deletion by using a B cell specific RhoA-ko mouse model (Zhang et 
al., 2012). Taken together, our data indicate that RhoA is dispensable for proliferation of DC, 
but deletion of RhoA leads to enhanced proliferation of cDC due to elevated Flt3L. 
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6.3 RhoA and DC survival 
Previous studies have shown that RhoA plays a crucial role in promoting cell survival 
(Hippenstiel et al., 2002; Reuveny et al., 2004; Zhu et al., 2008). We therefore studied DC 
apoptosis, and found significant increased TUNEL and Annexin-V positive cDCs in RhoA-ko 
mice (Fig. 13A,B). In addition, we observed significantly increased DCs accumulating in G2-
M phase of the cell cycle (Fig. 11A). Imagestream analysis showed that RhoA-deficient cDCs 
were arrested in anaphase and telophase during mitosis (Fig. 11C,D). It has been reported that 
RhoA is critical for regulating cleavage furrow formation and separation of two daughter cells 
during mitosis, deletion of which would lead to increased multi-nucleated cells (Geddis et al., 
2007; Lordier et al., 2008). Mitotic failure results in polyploid cells, which may trigger cell 
death (Castedo et al., 2004). Therefore, the observed mitotic failure in cDCs due to RhoA 
deficiency might lead to DC death. Recently, a pro-apoptosis protein BAD has been identified 
to contribute to mitotic cell death in mitochondrial apoptosis pathway (Diaz-Martinez et al., 
2014). The phosphorylation of BAD was clearly inhibited in RhoA-ko cDCs, which may be 
linked to mitotic cell death through the mitochondrial apoptosis pathway. However, it is still 
unclear if the increased apoptosis in RhoA-ko cDCs is caused by mitotic failure. Further work 
is required to find the correlation between mitotic failure and DC apoptosis.  
Our proteome analysis showed a pro-survival protein PI3Kγ significantly down-regulated in 
RhoA-deficient DCs. Previous studies have shown that deletion of PI3Kγ led to increased 
apoptosis of leukocytes (Rodrigues et al., 2010) and CD4+ T cells (Comerford et al., 2012) by 
using PI3Kγ-deficient mice. Furthermore, PI3Kγ-deficiency also caused significant decrease 
of cDCs in spleen (Del Prete et al., 2004), as well as death of migratory DCs in dLNs 
(Comerford et al., 2012). These DC reductions in PI3Kγ-deficient mice are quite consistent 
with our findings in RhoA-ko mice (Fig. 4A and Fig. 5A), suggesting PI3Kγ might play an 
important role in RhoA-regulated DC homeostasis. In RhoA-deficient DCs, the expression of 
PI3Kγ was strongly reduced, which led to inefficient phosphorylation and activation of its 
downstream effector Akt (Fig. 14B). Therefore, the pro-apoptotic protein BAD, a downstream 
target of Akt, cannot be effectively inactivated through phosphorylation. Consequently, more 
apoptosis was induced in RhoA-ko DC. However the mechanism of how RhoA regulates the 
expression of PI3Kγ in DC is still unclear. But we also found that RhoA deletion caused 
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significantly reduced transcription of PI3Kγ mRNA in spleen cDCs (Fig. 14C), suggesting a 
transcriptional regulation by RhoA. Previous studies have revealed that RhoA regulated gene 
transcriptions via modulating transcription factor GATA-4 (Charron et al., 2001) and the c-fos 
serum response element (SRE) (Hill et al., 1995). However, it is still unknown which 
transcription factors were utilized by RhoA to regulate expression of PI3Kγ in DCs. Therefore 
further analysis is required to investigate the mechanism of how RhoA regulates 
PI3Kγ/Akt/BAD pro-survival signaling pathway. Furthermore, other studies showed receptors 
for GM-CSF (Kohno et al., 2004; Muessel et al., 2008) and Flt3L (Mali et al., 2011) regulated 
cell migration and survival through RhoA signaling. Therefore, RhoA might act as a sensor of 
GM-CSF and Flt3L to promote DC survival, through regulating PI3Kγ/Akt/BAD signaling 
pathway.   
In summary, our findings revealed a crucial role for RhoA in regulating the homeostasis of 
cDCs in spleen. RhoA-deficient cDCs exhibited clearly increased apoptosis, resulting in 
significantly reduced numbers of cDCs in spleen. Proteome analysis suggests that RhoA 
maintains DC survival via PI3Kγ/Akt/BAD signaling pathway.  
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7. APPENDIX 
7.1 Proteomics data 
54 proteins were up-, and 39 proteins were down-regulated more than 3-fold in RhoA-
deficient BMDCs. These proteins are listed in the following table in the order of fold changes. 
With the help of Dr Stephan Müller (DZNE), the proteomics data have been deposited to the 
ProteomeXchange Consortium (Vizcaino et al., 2014) (www.proteomexchange.org) via the 
PRIDE partner repository with the dataset identifier PXD001636 (Username: 
reviewer17494@ebi.ac.uk; Password: FYSzY7vG).  
Table 3: Proteins differentially expressed between wt and RhoA-ko BMDCs. 
Gene Name 
 
Protein Name 
 
Fold change 
(RhoA-ko/Wt) 
Up-regulated (>3 fold) 
Vps13c Vacuolar protein sorting-associated protein 13C 23 
Lrp1 Low-density lipoprotein receptor-related protein 1 8 
Serpinb2 Plasminogen activator inhibitor 2, macrophage 7 
Selenbp1;2 Selenium-binding protein 1;2 7 
Mrc1 Macrophage mannose receptor 1 6 
Ctsd Cathepsin D 5 
Ctsb Cathepsin B 5 
Lrpap1 Alpha-2-macroglobulin receptor-associated protein 5 
Myof Myoferlin 5 
Lamp1 Lysosome-associated membrane glycoprotein 1 5 
Ephx1 Epoxide hydrolase 1 5 
Gpnmb Transmembrane glycoprotein NMB 5 
Pls3 Plastin-3 4 
Anxa3 Annexin A3 4 
Vat1 Synaptic vesicle membrane protein VAT-1 homolog 4 
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Flna Filamin-A 4 
Lyz2 Lysozyme C-2 4 
Cd36 Platelet glycoprotein 4 4 
Mgll Monoglyceride lipase 4 
Gda Guanine deaminase 4 
Atp6v0d2 V-type proton ATPase subunit d 2 4 
Lpl Lipoprotein lipase 4 
Fabp5 Fatty acid-binding protein, epidermal 4 
Idh1 Isocitrate dehydrogenase [NADP] 3 
Il1rn Interleukin-1 receptor antagonist protein 3 
Msr1 Macrophage scavenger receptor types I and II 3 
Asph Aspartyl/asparaginyl beta-hydroxylase 3 
Ahnak2 
 
3 
Hmox1 Heme oxygenase 1 3 
Blvrb Flavin reductase (NADPH) 3 
Gla Alpha-galactosidase A 3 
Aldh1a2 Retinal dehydrogenase 2 3 
Car4 Carbonic anhydrase 4 3 
Prdx5 Peroxiredoxin-5, mitochondrial 3 
Ddhd1 Phospholipase DDHD1 3 
Papss2 Sulfate adenylyltransferase 3 
Tmem106a Transmembrane protein 106A 3 
Nudt16 U8 snoRNA-decapping enzyme 3 
Stom Erythrocyte band 7 integral membrane protein 3 
Ctsl1 Cathepsin L1 3 
Tubb2a;Tubb2b Tubulin beta-2A chain;Tubulin beta-2B chain 3 
Dusp3 Dual specificity protein phosphatase 3 3 
Ass1 Argininosuccinate synthase 3 
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Aldh1l1 Cytosolic 10-formyltetrahydrofolate dehydrogenase 3 
Fabp4 Fatty acid-binding protein, adipocyte 3 
Lgals3bp Galectin-3-binding protein 3 
Gstm2 Glutathione S-transferase Mu 2 3 
Lgmn Legumain 3 
Ptgr1 Prostaglandin reductase 1 3 
Pfkl 6-phosphofructokinase, liver type 3 
Gstm1 Glutathione S-transferase Mu 1 3 
Ctsz Cathepsin Z 3 
Adssl1 Adenylosuccinate synthetase isozyme 1 3 
Ddx58 Probable ATP-dependent RNA helicase DDX58 3 
 
  Gene Name 
 
Protein Name 
 
Fold change 
(RhoA-ko/Wt) 
Down-regulated (>3 fold) 
Alox12l Arachidonate 12-lipoxygenase, leukocyte-type -18 
Avil Advillin -17 
Gbp2 Interferon-induced guanylate-binding protein 2 -13 
 
MLV-related proviral Env polyprotein -8 
Ctnnb1 Catenin beta-1 -7 
Card9 
 
-6 
Pik3cg Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma -6 
Lacc1 Laccase domain-containing protein 1 -5 
Trp53i11 Tumor protein p53-inducible protein 11 -5 
Rtn1 Reticulon-1 -5 
Ctnna1 Catenin alpha-1 -5 
Cdh1 Cadherin-1 -5 
Scin Adseverin -5 
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Aif1 Allograft inflammatory factor 1 -4 
Nedd4 E3 ubiquitin-protein ligase NEDD4 -4 
Lipe Hormone-sensitive lipase -4 
Ttc39b Tetratricopeptide repeat protein 39B -4 
L1cam Neural cell adhesion molecule L1 -4 
Pram1 PML-RARA-regulated adapter molecule 1 -4 
Tfrc Transferrin receptor protein 1 -4 
Pgm2l1 Glucose 1,6-bisphosphate synthase -4 
Grap2 GRB2-related adaptor protein 2 -3 
Kmo Kynurenine 3-monooxygenase -3 
Dok3 Docking protein 3 -3 
Tppp3 Tubulin polymerization-promoting protein 3 -3 
Cd2ap CD2-associated protein -3 
Mfge8 Lactadherin -3 
Glb1 Beta-galactosidase -3 
Enah Protein enabled homolog -3 
2010005H15Rik 
 
-3 
Bckdha 2-oxoisovalerate dehydrogenase subunit alpha -3 
Vrk1 Serine/threonine-protein kinase VRK1 -3 
Cst3 Cystatin-C -3 
H2-Eb1 H-2 class II histocompatibility antigen -3 
Hsd17b4 Peroxisomal multifunctional enzyme type 2 -3 
Plet1 Placenta-expressed transcript 1 protein -3 
H2-Aa H-2 class II histocompatibility antigen, A-B alpha chain -3 
Spn Leukosialin -3 
RhoA RhoA -3 
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8. ABBREVIATIONS 
ACK Ammonium chloride potassium 
APC Antigen presenting cell 
APC Allophycocyanin 
BM Bone marrow 
BMDC Bone marrow derived dendritic cells 
bp Base pair 
BrdU Bromodeoxyuridine 
CD Cluster of differentiation 
cDC Conventional dendritic cell 
cDNA Complementary DNA 
CSF1R Colony stimulating factor 1 receptor 
CTL Cytotoxic T lymphocyte 
CXCL C-X-C motif chemokine ligand 
CXCR C-X-C motif chemokine receptor 
DC Dendritic cell 
dLN Draining lymph node 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence activated cell sorter 
FCS Fetal calf serum 
FITC Fluoresceinisothiocyanate 
Flt3L FMS-like-tyrosine-kinase 3 ligand 
IFN Interferon 
GAP GTPase activating protein 
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GDI Guanine nucleotide dissociation factor 
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GTP Guanosine triphosphate 
HPCs Hematopoietic progenitor cells 
HPRT Hypoxanthine phosphoribosyltransferase 
i.p. / i.v. Intraperitoneal / intravenous 
IL Interleukin 
KO Knockout 
LN Lymph node 
LTβR Lymphotoxin-β receptor 
MACS Magnetic cell sorting 
mg, ml, mM, M Milligram, Milliliter, Millimolar, Molar 
min Minutes 
mRNA Messenger RNA 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
pDC Plasmacytoid DC 
PE Phycoerythrin 
PerCP Peridinin-Chlophyll 
pH Power of hydrogen 
qPCR Quantitative PCR 
RA  Recnoic acid 
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RT Room temperature 
SDS Sodium dodecyl sulfate 
TAE Tris-acetate-EDTA buffer 
TEMED Tetramethylethylenediamine 
TUNEL TdT-mediated dUTP-biotin nick end labeling 
WT Wild type 
μg, μl, μm Microgram, Microliter, Micrometer 
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